StocksFundsScreenerSectorsWatchlists
RXRX

RXRX - Recursion Pharmaceuticals, Inc. Stock Price, Fair Value and News

7.36USD-0.04 (-0.54%)Market Closed

Market Summary

RXRX
USD7.36-0.04
Market Closed
-0.54%

RXRX Alerts

  • 3 major insider sales recently.

RXRX Stock Price

View Fullscreen

RXRX RSI Chart

RXRX Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

-5.26

Price/Sales (Trailing)

38.68

EV/EBITDA

-4.33

Price/Free Cashflow

-5.75

RXRX Price/Sales (Trailing)

RXRX Profitability

EBT Margin

-745.10%

Return on Equity

-70.79%

Return on Assets

-50.19%

Free Cashflow Yield

-17.38%

RXRX Fundamentals

RXRX Revenue

Revenue (TTM)

44.6M

Rev. Growth (Yr)

-20.36%

Rev. Growth (Qtr)

3.4%

RXRX Earnings

Earnings (TTM)

-328.1M

Earnings Growth (Yr)

-61.75%

Earnings Growth (Qtr)

0.02%

Breaking Down RXRX Revenue

Last 7 days

-12.5%

Last 30 days

-33.5%

Last 90 days

-23.6%

Trailing 12 Months

35.3%

How does RXRX drawdown profile look like?

RXRX Financial Health

Current Ratio

4.7

RXRX Investor Care

Shares Dilution (1Y)

22.64%

Diluted EPS (TTM)

-1.58

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202346.6M50.0M47.4M44.6M
202212.9M18.1M28.7M39.8M
202125.2M8.8M10.3M10.2M
20202.7M3.1M3.6M4.0M
20190002.3M

Tracking the Latest Insider Buys and Sells of Recursion Pharmaceuticals, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 17, 2024
secora michael
acquired
83,250
2.22
37,500
chief financial officer
Apr 17, 2024
secora michael
sold
-175,349
7.583
-23,124
chief financial officer
Apr 16, 2024
borgeson blake
sold
-87,725
7.6636
-11,447
-
Apr 16, 2024
secora michael
acquired
83,250
2.22
37,500
chief financial officer
Apr 16, 2024
secora michael
sold
-191,658
7.6663
-25,000
chief financial officer
Apr 04, 2024
gibson christopher
sold
-225,500
9.02
-25,000
chief executive officer
Apr 04, 2024
gibson christopher
sold
-360,800
9.02
-40,000
chief executive officer
Apr 04, 2024
gibson christopher
acquired
-
-
25,000
chief executive officer
Apr 03, 2024
gibson christopher
gifted
-
-
-25,000
chief executive officer
Apr 03, 2024
gibson christopher
acquired
-
-
25,000
chief executive officer

1–10 of 50

Which funds bought or sold RXRX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 18, 2024
Capital Advisors, Ltd. LLC
new
-
7,000
7,000
-%
Apr 18, 2024
ARK Investment Management LLC
added
19.04
41,486,700
245,138,000
1.70%
Apr 18, 2024
Oxinas Partners Wealth Management LLC
new
-
122,133
122,133
0.08%
Apr 18, 2024
SJS Investment Consulting Inc.
unchanged
-
11.00
997
-%
Apr 17, 2024
Clarius Group, LLC
unchanged
-
3,146
285,152
0.02%
Apr 16, 2024
Financial Management Professionals, Inc.
new
-
8,000
8,000
-%
Apr 16, 2024
Stratos Wealth Partners, LTD.
new
-
133,957
133,957
-%
Apr 15, 2024
TB Alternative Assets Ltd.
new
-
705,876
705,876
0.18%
Apr 15, 2024
Kinnevik AB (publ)
unchanged
-
1,144,620
103,745,000
100.00%
Apr 15, 2024
EXCHANGE TRADED CONCEPTS, LLC
added
61.57
102,227
263,527
0.01%

1–10 of 48

Are Funds Buying or Selling RXRX?

Are funds buying RXRX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own RXRX
No. of Funds

Unveiling Recursion Pharmaceuticals, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
7.52%
15,665,210
SC 13G/A
Feb 12, 2024
ark investment management llc
11.08%
23,076,052
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G
Jan 29, 2024
blackrock inc.
6.0%
12,393,872
SC 13G/A
Jan 29, 2024
ark investment management llc
9.92%
20,654,287
SC 13G
Jan 26, 2024
baillie gifford & co
11.61%
24,179,504
SC 13G/A
Jan 24, 2024
state street corp
5.83%
12,151,646
SC 13G
May 22, 2023
kinnevik ab (publ)
5.6%
10,405,668
SC 13G
Feb 14, 2023
lux capital management, llc
3.3%
6,004,722
SC 13G/A
Feb 09, 2023
vanguard group inc
5.54%
10,057,363
SC 13G

Recent SEC filings of Recursion Pharmaceuticals, Inc.

View All Filings
Date Filed Form Type Document
Apr 18, 2024
4
Insider Trading
Apr 18, 2024
4
Insider Trading
Apr 17, 2024
144
Notice of Insider Sale Intent
Apr 16, 2024
144
Notice of Insider Sale Intent
Apr 16, 2024
144
Notice of Insider Sale Intent
Apr 16, 2024
144/A
144/A
Apr 16, 2024
8-K
Current Report
Apr 05, 2024
4
Insider Trading
Apr 04, 2024
144
Notice of Insider Sale Intent
Apr 04, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Recursion Pharmaceuticals, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
38.7B
6.8B
-1.66% -28.18%
-8.22
5.66
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.2B
1.8B
-2.46% -28.84%
-41.3
9.94
76.23% 61.08%
16.7B
2.4B
4.57% -8.46%
99.75
6.91
15.42% 18.43%
11.8B
3.7B
-10.11% -29.11%
19.67
3.18
8.87% 75.42%
MID-CAP
5.7B
396.6M
-14.37% -42.33%
-10.84
14.45
425.83% 18.94%
4.4B
-
-13.59% 50.21%
-6.66
60.35
54.84% -34.79%
3.2B
270.6M
-13.81% -4.67%
-13.46
11.9
440.80% -27.84%
2.8B
726.4M
-9.91% -15.82%
-45.19
3.81
40.45% 71.62%
2.8B
240.7M
-20.67% -25.33%
-9.33
12.18
-1.03% -92.09%
SMALL-CAP
1.8B
398.2M
-10.64% -8.42%
24.94
4.47
85.90% -14.05%
558.4M
983.7M
-17.39% -51.52%
-1.02
0.57
-50.36% 17.16%
409.4M
881.7K
-0.38% 387.14%
-9.18
466.16
-77.61% -5.33%
226.2M
4.9M
-10.29% -2.81%
-1.67
46.49
-54.97% 51.71%
6.0M
2.1M
59.81% 33.59%
-0.22
2.14
-13.45% 66.37%

Recursion Pharmaceuticals, Inc. News

Latest updates
Defense World2 hours ago
MarketBeat15 Apr 202409:50 pm
Nasdaq14 Mar 202407:00 am

Recursion Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Revenue3.4%10,891,00010,533,00011,017,00012,134,00013,676,00013,160,0007,674,0005,333,0002,533,0002,534,0002,549,0002,562,0002,691,0001,025,00018,943,000--
Costs and Expenses-0.2%109,821,000110,083,00092,732,00081,999,00074,658,00075,733,00073,865,00061,314,00067,493,00048,936,00043,478,00033,046,000-----
Operating Expenses---------67,493,00048,936,00043,478,00033,046,00028,272,00023,499,00018,403,00018,403,000-
  S&GA Expenses4.3%30,458,50029,199,00028,290,00022,874,00019,838,00019,488,00021,199,00021,074,00019,201,00015,690,00013,854,0008,937,0007,574,0006,964,0005,159,0005,561,000-
  R&D Expenses-0.7%69,482,00070,007,00055,060,00046,677,00043,980,00040,836,00038,439,00032,441,00048,292,00033,246,00029,624,00024,109,00020,698,00016,535,00013,244,00012,842,000-
EBITDA Margin-Infinity%-6.90----------------
Interest Expenses445.5%60,00011,00012,00013,00013,00014,00014,00014,00015,000125,000286,000254,000166,000101,000416,000306,000-
EBT Margin-Infinity%-7.45----------------
Net Income0.0%-92,996,000-93,017,000-76,726,000-65,327,000-57,492,000-60,445,000-65,560,000-55,979,000-64,933,000-47,428,000-43,401,000-30,717,000-25,766,000-23,873,000-18,943,000-18,424,000-
Net Income Margin-19.1%-7.36-6.18-5.20-5.33-6.01-8.60-12.94-16.35-18.32-14.25-14.02-3.94-21.96-17.42-19.70-22.67-26.68
Free Cashflow-3.4%-76,144,000-73,665,000-71,435,000-78,491,000-52,727,000-62,804,000-78,098,00073,046,000-65,622,000-42,754,000-39,865,000-50,171,0004,886,000-20,282,000-17,333,000-18,501,000-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q4
Assets3.6%654631667627701612673734610659699272299
  Current Assets6.7%438411431492570482546619535601648222266
    Cash Equivalents1.1%392387406473550465464518295405643219267
  Net PPE0.3%87.0086.0090.0090.0088.0086.0082.0071.0065.0055.0049.0045.0026.00
  Goodwill-1.3%52.0053.0061.001.001.001.001.001.001.00---1.00
Liabilities-1.3%19019319819721522323524167.0060.0056.0057.0057.00
  Current Liabilities-1.0%93.0094.0011492.0010083.0097.0086.0047.0043.0030.0027.0023.00
Shareholder's Equity5.8%463438469430486388438494543599643--206
  Retained Earnings-10.6%-967-874-781-704-639-582-521-456-400-335-287-244-213
  Additional Paid-In Capital9.0%1,4311,3131,2511,1351,12597095995094393493011.007.00
Shares Outstanding8.3%23421620719219117217117112511181.0023.0022.00
Float---930---941---3,900--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Cashflow From Operations-1.6%-74,077-72,920-67,467-73,316-44,748-54,541-61,62377,388-61,158-33,048-33,653-30,7558,573-19,456-16,699-17,817-
  Share Based Compensation-4.2%16,08616,79211,8118,8147,6958,9075,6755,6324,3413,3635,3171,8211,1881,0707691,265-
Cashflow From Investing-617.0%-2,488-347-2,053-5,340-7,97952,9844,940143,304-52,243-193,873-6,212-19,416-4,591-3,426-39.00-684-
Cashflow From Financing50.0%80,65953,7653,7871,922147,2562,3372,6682,0843,796-11,095463,7052,13410,035229,7213825,997-

RXRX Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue   
Revenue$ 44,575$ 39,843$ 10,178
Operating costs and expenses   
Cost of revenue42,58748,2750
Research and development241,226155,696135,271
General and administrative110,82281,59957,682
Total operating costs and expenses394,635285,570192,953
Loss from operations(350,060)(245,727)(182,775)
Other income (loss), net17,9326,251(3,704)
Loss before income tax benefit(332,128)(239,476)(186,479)
Income tax benefit4,06200
Net loss$ (328,066)$ (239,476)$ (186,479)
Per share data   
Net loss per share of Class A, B and Exchangeable common stock, basic (in dollars per share)$ (1.58)$ (1.36)$ (1.49)
Net loss per share of Class A, B and Exchangeable common stock, diluted (in dollars per share)$ (1.58)$ (1.36)$ (1.49)
Weighted-average shares (Class A, B and Exchangeable) outstanding, basic (in shares)207,853,702175,537,487125,348,110
Weighted-average shares (Class A, B and Exchangeable) outstanding, diluted (in shares)207,853,702175,537,487125,348,110
Operating revenue   
Revenue   
Revenue$ 43,876$ 39,681$ 10,000
Grant revenue   
Revenue   
Revenue$ 699$ 162$ 178

RXRX Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 391,565$ 549,912
Restricted cash3,2311,280
Other receivables3,0942,753
Other current assets40,24715,869
Total current assets438,137569,814
Restricted cash, non-current6,6297,920
Property and equipment, net86,51088,192
Operating lease right-of-use assets33,66333,255
Intangible assets, net36,4431,306
Goodwill52,056801
Other assets, non-current2610
Total assets653,699701,288
Current liabilities  
Accounts payable3,9534,586
Accrued expenses and other liabilities46,63532,904
Unearned revenue36,42656,726
Notes payable4197
Operating lease liabilities6,1165,952
Total current liabilities93,171100,265
Unearned revenue, non-current51,23870,261
Notes payable, non-current1,101536
Operating lease liabilities, non-current43,41444,420
Deferred tax liabilities1,3390
Total liabilities190,263215,482
Commitments and contingencies (Note 7)
Stockholders’ equity  
Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of December 31, 2023 and December 31, 2022; 234,270,384 shares (Class A 226,264,764, Class B 7,544,871 and Exchangeable 460,749) and 191,022,864 (Class A 183,209,655 and Class B 7,813,209 and Exchangeable —) issued and outstanding as of December 31, 2023 and December 31, 2022, respectively22
Additional paid-in capital1,431,0561,125,360
Accumulated deficit(967,622)(639,556)
Total stockholders’ equity463,436485,806
Total liabilities and stockholders’ equity$ 653,699$ 701,288
RXRX
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
 CEO
 WEBSITErecursion.com
 INDUSTRYBiotechnology
 EMPLOYEES550

Recursion Pharmaceuticals, Inc. Frequently Asked Questions


What is the ticker symbol for Recursion Pharmaceuticals, Inc.? What does RXRX stand for in stocks?

RXRX is the stock ticker symbol of Recursion Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Recursion Pharmaceuticals, Inc. (RXRX)?

As of Fri Apr 19 2024, market cap of Recursion Pharmaceuticals, Inc. is 1.72 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RXRX stock?

You can check RXRX's fair value in chart for subscribers.

What is the fair value of RXRX stock?

You can check RXRX's fair value in chart for subscribers. The fair value of Recursion Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Recursion Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RXRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Recursion Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether RXRX is over valued or under valued. Whether Recursion Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Recursion Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RXRX.

What is Recursion Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, RXRX's PE ratio (Price to Earnings) is -5.26 and Price to Sales (PS) ratio is 38.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RXRX PE ratio will change depending on the future growth rate expectations of investors.